Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misrepresenting its capital allocation priorities and significantly reducing its quarterly dividend [1][7]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey [1]. - Investors who acquired Organon shares during the class period (October 31, 2024 – April 30, 2025) are encouraged to contact the law firm before the lead plaintiff motion deadline on July 22, 2025 [1][3][7]. Group 2: Allegations Against Organon - Organon is accused of concealing material information regarding its capital allocation priorities, particularly in relation to its quarterly dividend [7]. - The company publicly emphasized dividends as a top priority while internally shifting focus towards debt reduction [7]. - Following the acquisition of Dermavant Sciences Ltd., Organon drastically reduced its quarterly dividend by over 90% [7]. Group 3: Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP has over 125 years of legal expertise in securities litigation and aims to protect the rights of investors [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for misleading investors regarding its dividend policy following a significant acquisition [1][3]. Company Overview - Organon & Co. is a healthcare company based in Jersey City, NJ, focusing on women's health [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Financial Developments - Following the Dermavant acquisition, Organon increased its debt but assured investors that maintaining its dividend was a top priority [3]. - On May 1, 2025, Organon announced a drastic reduction in its dividend payout from $0.28 per share to $0.02 per share, indicating a shift in capital allocation priorities towards deleveraging [3]. - This announcement led to a significant decline in Organon's stock price, dropping approximately 27% from $12.93 to $9.45 per share [3].

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2] - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4]

Group 1 - A class action lawsuit has been filed on behalf of purchasers of Organon & Co. securities between October 31, 2024, and April 30, 2025 [1] - Investors who purchased Organon securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Organon's management provided misleading statements regarding the company's priorities, particularly concerning capital allocation and a significant reduction in quarterly dividends [5] Group 2 - The lawsuit claims that Organon concealed the importance of its debt reduction strategy following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [5] - Investors are encouraged to join the class action by contacting the Rosen Law Firm for more information [3][6] - The Rosen Law Firm has a strong track record in securities class actions, having recovered hundreds of millions of dollars for investors and being recognized for its success in this area [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing adverse facts about its priorities, particularly regarding capital allocation and a significant debt reduction strategy following the acquisition of Dermavant [3]. - The company’s regular quarterly dividend was reduced by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is July 22, 2025, and there is no cost or obligation to participate in the case [4]. Firm's Commitment - The Gross Law Firm aims to protect the rights of investors affected by deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation priorities following the acquisition of Dermavant [1][3]. Company Overview - Organon & Co. is a healthcare company focused on women's health, headquartered in Jersey City, NJ [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3]. - The suit alleges that after the acquisition, Organon shifted its focus to reducing debt rather than maintaining dividend payouts [3]. Stock Price Reaction - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, stating that returning capital to shareholders was a lower priority [4]. - Following this announcement, Organon's stock price fell by $3.48 per share, approximately 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4].

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lead ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in stock price [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from October 31, 2024, to April 30, 2025 [2]. - Allegations include that Organon provided overly positive statements while concealing material adverse facts about its capital allocation priorities, particularly regarding debt reduction after the acquisition of Dermavant [2]. - Following the announcement of a 70% decrease in the regular quarterly dividend, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in one day [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 22, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for failing to disclose material information during the class period, which has led to significant financial repercussions for investors [3][4]. Group 1: Lawsuit Details - Investors have until July 22, 2025, to file lead plaintiff applications if they purchased Organon securities between October 31, 2024, and April 30, 2025 [1]. - The lawsuit is pending in the United States District Court for the District of New Jersey, under the case name Hauser V. Organon & Co., et al., No. 25-cv-05322 [5]. - The company and certain executives are accused of violating federal securities laws by not disclosing critical information during the class period [3]. Group 2: Financial Impact - On March 10, 2025, Organon announced a significant reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors regarding the importance of maintaining the dividend [4]. - Following the announcement, Organon's share price dropped over 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4]. Group 3: Investor Support - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information on various cases [6]. - Investors can upload their portfolio data to receive notifications about relevant securities cases and can seek free case evaluations from the law firm Kahn Swick & Foti, LLC [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Organon between October 31, 2024 and April 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...